Seite auswählen

The biotech company Qiagen and Bayer HealthCare will cooperate in the future in cancer diagnostics. Together, diagnostics for new drugs will be developed and marketed by Bayer. Personalised medicine, ie the targeted treatment of patients according to their genetic characteristics, is considered one of the fastest growing markets in the pharmaceutical industry. The beginning of the partnership development project makes for better treatment of patients with various solid tumours.
In addition, the two companies will jointly develop new technologies for the profiling of patients. Financial details of the agreement were not disclosed.


[ilink url=““] Link zur Quelle ([/ilink]